ImageneBio, Inc. (IMA)
NASDAQ
Key stats Fiscal year 2025
Income statement
- Revenue
- 800,000 -77.1%
- Net income
- -45,349,000
- Operating income
- -48,451,000
- Earnings per share
- -9.64
- R&D expense
- 28,525,000
Growth and profitability
- Operating margin
- -6,056.38
- Net margin
- -5,668.63
- Return on equity
- -34.06
- Return on assets
- -29.64
Balance sheet
- Total assets
- 152,976,000
- Total liabilities
- 19,837,000
- Shareholders' equity
- 133,139,000
- Cash and equivalents
- 94,532,000
- Current ratio
- 12.49
Cash flow and ratios
- Operating cash flow
- -47,844,000
Shareholder returns
- Shares outstanding
- 12,456,281
- Book value per share
- 10.69
Company information
- Headquarters
- San Diego, CA
- Exchange
- NASDAQ
- Fiscal year end
- 12-31
- Industry (SEC)
- Biological Products, (no Diagnostic Substances)
Fiscal year end: · Source: SEC EDGAR
ImageneBio, Inc. trades on NASDAQ under the ticker symbol IMA. This page brings together its price chart, company profile, key financial figures and technical indicators.